Immunic Depreciation & Amortization Growth & History (IMUX)
Immunic's depreciation and amortization was $168,000 for fiscal 2025.
View full Immunic company overviewImmunic annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $168,000 | $34,000 | +25.37% |
| 2024 | 2024-12-31 | $134,000 | $23,000 | +20.72% |
| 2023 | 2023-12-31 | $111,000 | $34,000 | +44.16% |
| 2022 | 2022-12-31 | $77,000 | −$8,000 | −9.41% |
| 2021 | 2021-12-31 | $85,000 | $46,000 | +117.95% |
| 2020 | 2020-12-31 | $39,000 | −$11,000 | −22.00% |
| 2019 | 2019-12-31 | $50,000 | $35,000 | +233.33% |
| 2018 | 2018-12-31 | $15,000 | −$983,000 | −98.50% |
| 2017 | 2017-12-31 | $998,000 | −$810,000 | −44.80% |
| 2016 | 2016-12-31 | $1.8M | $480,000 | +36.14% |
| 2015 | 2015-12-31 | $1.3M | $241,000 | +22.17% |
| 2014 | 2014-12-31 | $1.1M | $288,000 | +36.05% |
| 2013 | 2013-12-31 | $799,000 | $148,000 | +22.73% |
| 2012 | 2012-12-31 | $651,000 | — | — |
Immunic quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $34,000 | −$9,000 | −20.93% |
| Q1 2026 | 2026-03-31 | $33,000 | −$10,000 | −23.26% |
| Q4 2025 | 2025-12-31 | $42,000 | — | — |
| Q3 2025 | 2025-09-30 | $40,000 | −$2,000 | −4.76% |
| Q2 2025 | 2025-06-30 | $43,000 | $12,000 | +38.71% |
| Q1 2025 | 2025-03-31 | $43,000 | $17,000 | +65.38% |
| Q3 2024 | 2024-09-30 | $42,000 | $8,000 | +23.53% |
| Q2 2024 | 2024-06-30 | $31,000 | $9,000 | +40.91% |
| Q1 2024 | 2024-03-31 | $26,000 | −$6,000 | −18.75% |
| Q3 2023 | 2023-09-30 | $34,000 | $17,000 | +100.00% |
| Q2 2023 | 2023-06-30 | $22,000 | $2,000 | +10.00% |
| Q1 2023 | 2023-03-31 | $32,000 | $11,000 | +52.38% |
| Q3 2022 | 2022-09-30 | $17,000 | $1,000 | +6.25% |
| Q2 2022 | 2022-06-30 | $20,000 | $5,000 | +33.33% |
| Q1 2022 | 2022-03-31 | $21,000 | $7,000 | +50.00% |
| Q3 2021 | 2021-09-30 | $16,000 | −$27,000 | −62.79% |
| Q2 2021 | 2021-06-30 | $15,000 | $9,000 | +150.00% |
| Q1 2021 | 2021-03-31 | $14,000 | $0 | 0.00% |
| Q3 2020 | 2020-09-30 | $43,000 | $34,000 | +377.78% |
| Q2 2020 | 2020-06-30 | $6,000 | −$18,000 | −75.00% |
| Q1 2020 | 2020-03-31 | $14,000 | $9,000 | +180.00% |
| Q3 2019 | 2019-09-30 | $9,000 | −$195,000 | −95.59% |
| Q2 2019 | 2019-06-30 | $24,000 | −$176,000 | −88.00% |
| Q1 2019 | 2019-03-31 | $5,000 | −$219,000 | −97.77% |
| Q3 2018 | 2018-09-30 | $204,000 | −$12,000 | −5.56% |
| Q2 2018 | 2018-06-30 | $200,000 | −$29,000 | −12.66% |
| Q1 2018 | 2018-03-31 | $224,000 | −$111,000 | −33.13% |
| Q3 2017 | 2017-09-30 | $216,000 | −$204,000 | −48.57% |
| Q2 2017 | 2017-06-30 | $229,000 | −$261,000 | −53.27% |
| Q1 2017 | 2017-03-31 | $335,000 | −$159,000 | −32.19% |
| Q3 2016 | 2016-09-30 | $420,000 | $95,000 | +29.23% |
| Q2 2016 | 2016-06-30 | $490,000 | $162,000 | +49.39% |
| Q1 2016 | 2016-03-31 | $494,000 | $200,000 | +68.03% |
| Q3 2015 | 2015-09-30 | $325,000 | $15,000 | +4.84% |
| Q2 2015 | 2015-06-30 | $328,000 | $82,000 | +33.33% |
| Q1 2015 | 2015-03-31 | $294,000 | −$3,000 | −1.01% |
| Q3 2014 | 2014-09-30 | $310,000 | $54,000 | +21.09% |
| Q2 2014 | 2014-06-30 | $246,000 | $72,000 | +41.38% |
| Q1 2014 | 2014-03-31 | $297,000 | $134,000 | +82.21% |
| Q3 2013 | 2013-09-30 | $256,000 | — | — |
| Q2 2013 | 2013-06-30 | $174,000 | — | — |
| Q1 2013 | 2013-03-31 | $163,000 | — | — |
Immunic depreciation and amortization trends
Over the last five fiscal years, Immunic's depreciation and amortization increased from $39,000 to $168,000, a change of $129,000. The latest reported quarter, Q2 2026, shows $34,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunic source filings ↗